Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INPPL1 | O15357 | 10/20 | 0.59 |
| ▸ | INPP5A | Q14642 | 6/20 | 0.59 |
| ▸ | SRC | P12931 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | INPP5B | P32019 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5705521 | 0.82 | INPPL1 (0.53) | INPPL1INPP5ASRCCA1CA2 | |
| SCHEMBL19435239 | 0.82 | INPPL1 (0.53) | INPPL1INPP5ASRCCA1CA2 | |
| SCHEMBL11039261 | 0.82 | INPPL1 (0.53) | INPPL1INPP5ASRCCA1CA2 | |
| SCHEMBL8386637 | 0.79 | INPPL1 (0.65) | INPPL1INPP5ASRCCA1CA2 | |
| SCHEMBL131227 | 0.79 | SRC (0.62) | INPPL1INPP5ASRCCA1CA2 | |
| SCHEMBL21585530 | 0.79 | INPPL1 (0.55) | INPPL1INPP5ASRCCA1CA2 | |
| SCHEMBL4190769 | 0.79 | TYR (0.61) | INPPL1INPP5ASRCCA1CA2 | |
| SCHEMBL329313 | 0.78 | SRC (0.75) | INPPL1INPP5ASRCCA1CA2 | |
| SCHEMBL11575621 | 0.77 | ALDH1A1 (0.57) | INPPL1INPP5A | |
| SCHEMBL28420405 | 0.77 | SRC (0.60) | INPPL1INPP5ASRCCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2722101-B1 | REVERSE-OSMOSIS MEMBRANE HAVING AN ULTRA-HYDROPHILIC PROTECTIVE LAYER AND METHOD FOR PRODUCING SAME | LG CHEMICAL LTD (KR) | 2018-10-24 | — | — | EP | claimed |
| US-8770414-B2 | Reverse osmosis membrane including ultra-hydrophilic passivation layer and method of manufacturing the same | LG CHEM, LTD. (KR) | 2014-07-08 | — | — | US | claimed |
| EP-2722101-A2 | REVERSE-OSMOSIS MEMBRANE HAVING AN ULTRA-HYDROPHILIC PROTECTIVE LAYER AND METHOD FOR PRODUCING SAME | LG Chem, Ltd. (KR) | 2014-04-23 | — | — | EP | claimed |
| US-20130284663-A1 | REVERSE OSMOSIS MEMBRANE INCLUDING ULTRA-HYDROPHILIC PASSIVATION LAYER AND METHOD OF MANUFACTURING THE SAME | LG CHEM, LTD. (KR) | 2013-10-31 | — | — | US | claimed |
| US-8142953-B2 | Hydrophilic adjuvant | LG CHEM, LTD. (KR) | 2012-03-27 | — | — | US | claimed |
| US-20100167168-A1 | Hydrophilic Adjuvant | LG CHEM, LTD. (KR) | 2010-07-01 | — | — | US | claimed |
| WO-2007069867-A1 | HYDROPHILIC ADJUVANT | LG CHEM, LTD (KR) | 2007-06-21 | — | — | WO | claimed |
| EP-2722101-B1 | REVERSE-OSMOSIS MEMBRANE HAVING AN ULTRA-HYDROPHILIC PROTECTIVE LAYER AND METHOD FOR PRODUCING SAME | LG CHEMICAL LTD (KR) | 2018-10-24 | — | — | EP | disclosed |
| US-8770414-B2 | Reverse osmosis membrane including ultra-hydrophilic passivation layer and method of manufacturing the same | LG CHEM, LTD. (KR) | 2014-07-08 | — | — | US | disclosed |
| EP-2722101-A2 | REVERSE-OSMOSIS MEMBRANE HAVING AN ULTRA-HYDROPHILIC PROTECTIVE LAYER AND METHOD FOR PRODUCING SAME | LG Chem, Ltd. (KR) | 2014-04-23 | — | — | EP | disclosed |
| US-20130284663-A1 | REVERSE OSMOSIS MEMBRANE INCLUDING ULTRA-HYDROPHILIC PASSIVATION LAYER AND METHOD OF MANUFACTURING THE SAME | LG CHEM, LTD. (KR) | 2013-10-31 | — | — | US | disclosed |
| US-8142953-B2 | Hydrophilic adjuvant | LG CHEM, LTD. (KR) | 2012-03-27 | — | — | US | disclosed |
| US-20100167168-A1 | Hydrophilic Adjuvant | LG CHEM, LTD. (KR) | 2010-07-01 | — | — | US | disclosed |
| WO-2007069867-A1 | HYDROPHILIC ADJUVANT | LG CHEM, LTD (KR) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100167168-A1 | Hydrophilic Adjuvant | CD44, CD74, LY96 | INPPL1 311/4885INPP5A 1668/4885SRC 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.